Home / Market News / $SLN
benzinga Corporate Catalyst Impact 95/100 ● positive

Merck KGaA Agrees To Acquire Silence Therapeutics For $20 Per ADS In Cash

Oct 19, 2026, 12:01 PM UTC · Primary ticker $SLN

Merck KGaA announced a definitive agreement to acquire Silence Therapeutics for $1.3 billion in cash, representing a significant premium to Silence Therapeutics' recent trading price. This acquisition marks a major strategic move for Merck KGaA into siRNA therapies and provides a substantial payout for Silence Therapeutics shareholders.

Merck KGaA is acquiring Silence Therapeutics, a clinical-stage biotechnology company specializing in siRNA therapies, for an equity value of approximately $1.3 billion. This all-cash deal offers Silence Therapeutics shareholders $20 per ADS, an 82% premium over its 30-day volume-weighted average price, indicating a strong positive short-term impact for SLN investors. For Merck KGaA, this acquisition represents a strategic expansion into a promising therapeutic area, potentially enhancing its long-term pipeline and market position. Traders should note the immediate upside for SLN due to the premium, while MRK's stock might see a neutral to slightly negative short-term reaction due to the acquisition cost, balanced by the long-term strategic benefits.

$SLN positive Acquired at significant premium
$MRK neutral Acquirer, strategic expansion
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.